Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Asia Green Biotechnology Corp. (C:ASIA)

Business Focus: Alternative Medicine

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for ASIA within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Feb 09, 2021 15:00 ET
Asia Green Biotechnology Corp. Expands Technology Development Relationship with Pathway Rx Inc. and Swysh Inc. with Agreement to Undertake Initial Toxicity Testing for Migraine Study
CALGARY, AB / ACCESSWIRE / February 9, 2021 / Asia Green Biotechnology Corp. ("AGB" or the "Company") (CSE:ASIA) is pleased to announce that it has entered an agreement with Pathway Rx Inc. ("Pathway Rx") and Swysh Inc. ("Swysh") pursuant to which AGB has expanded its commitment to assist in the develop and commercialize the Cannabis sativa varieties to which Pathway Rx Inc. and Swysh Inc. own the rights for prevention and treatment of certain infectious diseases. Both Pathway and Swysh have previously entered agreements with the Company to
Read full article
Jan 22, 2021 09:00 ET
Asia Green Biotechnology Corp. Announces Appointment of Alisdair Leeson To Board of Directors
CALGARY, AB / ACCESSWIRE / January 22, 2021 / Asia Green Biotechnology Corp. ("AGB" or the "Company") (CSE:ASIA), announced today that, subject to regulatory approval, Mr. Alisdair Leeson, CA, has been appointed as a member of the Board of Directors.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
--
13.22
15.17
Price to Book - most recent quarter
11.42
3.21
4.43
Price to Cash Flow per share - TTM
--
13.80
15.66
Price to Free Cash Flow per share - TTM
--
33.60
28.14
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Feb 28, 202193-2,007
Feb 15, 20212,1002,009
Jan 31, 202191-396
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Asia Green Biotechnology Corp., formerly, Asia Cannabis Corp. is a Canada-based early-stage international agri-technology company. The Company centered on the planting, growing, and harvesting of valuable strains of hemp and related crops in commercial quantities in South Asia. The Company's technology secures exposure to and capacities in the hemp and related sectors through horticultural, scientific, genetic and genomic. The Company's products include food, fuel, fiber and foundation.

See business summary

 

Twitter

Search (past week) for $ASIA.CA

  • No tweets found